77 related articles for article (PubMed ID: 3986814)
21. [Therapy-induced leukemia -- an underestimated complication of antineoplastic chemotherapy?].
Dührsen U
Zentralbl Gynakol; 2005 Aug; 127(4):235-41. PubMed ID: 16037905
[TBL] [Abstract][Full Text] [Related]
22. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.
van der Kaaij MA; Heutte N; Le Stang N; Raemaekers JM; Simons AH; Carde P; Noordijk EM; Fermé C; Thomas J; Eghbali H; Kluin-Nelemans HC; Henry-Amar M; ;
J Clin Oncol; 2007 Jul; 25(19):2825-32. PubMed ID: 17515571
[TBL] [Abstract][Full Text] [Related]
23. Measuring the genetic damage in cancer patients during radiotherapy with three genetic end-points.
Jianlin L; Jiliang H; Lifen J; Wei Z; Baohong W; Hongping D
Mutagenesis; 2004 Nov; 19(6):457-64. PubMed ID: 15548757
[TBL] [Abstract][Full Text] [Related]
24. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
25. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.
Simone CB; Simone NL; Simone V; Simone CB
Altern Ther Health Med; 2007; 13(1):22-8. PubMed ID: 17283738
[TBL] [Abstract][Full Text] [Related]
26. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.
De Benedetti VM; Travis LB; Welsh JA; van Leeuwen FE; Stovall M; Clarke EA; Boice JD; Bennett WP
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):93-8. PubMed ID: 8850268
[TBL] [Abstract][Full Text] [Related]
27. [Long-term sequelae of malignant tumors in childhood: consequences of late side-effects].
Peretz NM; Goldberg H; Kuten A; Meller I; Krivoi E; Lorber A; Bentur L; Lightman A; Gorenberg V; Ben Arush-Weyl M
Harefuah; 2001 Feb; 140(2):95-100, 192, 191. PubMed ID: 11242936
[TBL] [Abstract][Full Text] [Related]
28. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy in older cancer patients.
Leslie WT
Oncology (Williston Park); 1992 Feb; 6(2 Suppl):74-80. PubMed ID: 1532741
[TBL] [Abstract][Full Text] [Related]
30. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
31. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
32. Possible genetic effects of cancer therapy, seen in surviving cancer patients' offspring.
Oftedal P; Mulvihill J
Prog Clin Biol Res; 1986; 209B():351-6. PubMed ID: 3749094
[No Abstract] [Full Text] [Related]
33. The assessment of in vivo somatic mutations in survivors of childhood malignancy.
Hewitt M; Mott MG
Br J Cancer; 1992 Jul; 66(1):143-7. PubMed ID: 1637665
[TBL] [Abstract][Full Text] [Related]
34. Infections in patients with solid tumors.
McCormick RD
Nurs Clin North Am; 1985 Mar; 20(1):199-205. PubMed ID: 3844819
[TBL] [Abstract][Full Text] [Related]
35. [Second tumors following chemotherapy of malignant tumors].
Schmähl D
Arzneimittelforschung; 1987 Feb; 37(2A):288-90. PubMed ID: 3566874
[TBL] [Abstract][Full Text] [Related]
36. [Mutator hypothesis of carcinogenesis and supermutagens in anticancer therapy].
Krutiakov VM
Vestn Ross Akad Med Nauk; 2009; (9):39-43. PubMed ID: 19827641
[TBL] [Abstract][Full Text] [Related]
37. The mutational footprints of cancer therapies.
Pich O; Muiños F; Lolkema MP; Steeghs N; Gonzalez-Perez A; Lopez-Bigas N
Nat Genet; 2019 Dec; 51(12):1732-1740. PubMed ID: 31740835
[TBL] [Abstract][Full Text] [Related]
38. Parental mutagenesis and familial cancer.
Evans HJ
Nature; 1982 Apr; 296(5857):488-9. PubMed ID: 7070495
[No Abstract] [Full Text] [Related]
39. THE EFFECT OF VARYING THE DURATION OF X-RAY TREATMENT UPON THE FREQUENCY OF MUTATION.
Oliver CP
Science; 1930 Jan; 71(1828):44-6. PubMed ID: 17806621
[No Abstract] [Full Text] [Related]
40. Simulating the Dynamic Intra-Tumor Heterogeneity and Therapeutic Responses.
Liu Y; Feng C; Zhou Y; Shao X; Chen M
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
